139 related articles for article (PubMed ID: 18639280)
1. Is vascular endothelial growth factor modulation a predictor of the therapeutic efficacy of gefitinib for bladder cancer?
Kassouf W; Brown GA; Black PC; Fisher MB; Inamoto T; Luongo T; Gallagher D; Bar-Eli M; McConkey DJ; Adam L; Dinney CP
J Urol; 2008 Sep; 180(3):1146-53. PubMed ID: 18639280
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of the therapeutic potential of the epidermal growth factor receptor tyrosine kinase inhibitor gefitinib in preclinical models of bladder cancer.
Dominguez-Escrig JL; Kelly JD; Neal DE; King SM; Davies BR
Clin Cancer Res; 2004 Jul; 10(14):4874-84. PubMed ID: 15269164
[TBL] [Abstract][Full Text] [Related]
3. Schedule dependent efficacy of gefitinib and docetaxel for bladder cancer.
Kassouf W; Luongo T; Brown G; Adam L; Dinney CP
J Urol; 2006 Aug; 176(2):787-92. PubMed ID: 16813948
[TBL] [Abstract][Full Text] [Related]
4. The proteasome inhibitor bortezomib synergizes with gemcitabine to block the growth of human 253JB-V bladder tumors in vivo.
Kamat AM; Karashima T; Davis DW; Lashinger L; Bar-Eli M; Millikan R; Shen Y; Dinney CP; McConkey DJ
Mol Cancer Ther; 2004 Mar; 3(3):279-90. PubMed ID: 15026548
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of tumorigenicity and metastasis of human bladder cancer growing in athymic mice by interferon-beta gene therapy results partially from various antiangiogenic effects including endothelial cell apoptosis.
Izawa JI; Sweeney P; Perrotte P; Kedar D; Dong Z; Slaton JW; Karashima T; Inoue K; Benedict WF; Dinney CP
Clin Cancer Res; 2002 Apr; 8(4):1258-70. PubMed ID: 11948141
[TBL] [Abstract][Full Text] [Related]
6. Paclitaxel enhances the effects of the anti-epidermal growth factor receptor monoclonal antibody ImClone C225 in mice with metastatic human bladder transitional cell carcinoma.
Inoue K; Slaton JW; Perrotte P; Davis DW; Bruns CJ; Hicklin DJ; McConkey DJ; Sweeney P; Radinsky R; Dinney CP
Clin Cancer Res; 2000 Dec; 6(12):4874-84. PubMed ID: 11156247
[TBL] [Abstract][Full Text] [Related]
7. Uncoupling between epidermal growth factor receptor and downstream signals defines resistance to the antiproliferative effect of Gefitinib in bladder cancer cells.
Kassouf W; Dinney CP; Brown G; McConkey DJ; Diehl AJ; Bar-Eli M; Adam L
Cancer Res; 2005 Nov; 65(22):10524-35. PubMed ID: 16288045
[TBL] [Abstract][Full Text] [Related]
8. Frequent administration of angiogenesis inhibitor TNP-470 (AGM-1470) at an optimal biological dose inhibits tumor growth and metastasis of metastatic human transitional cell carcinoma in the urinary bladder.
Inoue K; Chikazawa M; Fukata S; Yoshikawa C; Shuin T
Clin Cancer Res; 2002 Jul; 8(7):2389-98. PubMed ID: 12114444
[TBL] [Abstract][Full Text] [Related]
9. Novel targeted approaches to treating biliary tract cancer: the dual epidermal growth factor receptor and ErbB-2 tyrosine kinase inhibitor NVP-AEE788 is more efficient than the epidermal growth factor receptor inhibitors gefitinib and erlotinib.
Wiedmann M; Feisthammel J; Blüthner T; Tannapfel A; Kamenz T; Kluge A; Mössner J; Caca K
Anticancer Drugs; 2006 Aug; 17(7):783-95. PubMed ID: 16926628
[TBL] [Abstract][Full Text] [Related]
10. Antitumor activity of the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor gefitinib (ZD1839, Iressa) in non-small cell lung cancer cell lines correlates with gene copy number and EGFR mutations but not EGFR protein levels.
Helfrich BA; Raben D; Varella-Garcia M; Gustafson D; Chan DC; Bemis L; Coldren C; Barón A; Zeng C; Franklin WA; Hirsch FR; Gazdar A; Minna J; Bunn PA
Clin Cancer Res; 2006 Dec; 12(23):7117-25. PubMed ID: 17145836
[TBL] [Abstract][Full Text] [Related]
11. Effect of combination therapy with a novel bisphosphonate, minodronate (YM529), and docetaxel on a model of bone metastasis by human transitional cell carcinoma.
Inoue K; Karashima T; Fukata S; Nomura A; Kawada C; Kurabayashi A; Furihata M; Ohtsuki Y; Shuin T
Clin Cancer Res; 2005 Sep; 11(18):6669-77. PubMed ID: 16166446
[TBL] [Abstract][Full Text] [Related]
12. Anti-epidermal growth factor receptor antibody C225 inhibits angiogenesis in human transitional cell carcinoma growing orthotopically in nude mice.
Perrotte P; Matsumoto T; Inoue K; Kuniyasu H; Eve BY; Hicklin DJ; Radinsky R; Dinney CP
Clin Cancer Res; 1999 Feb; 5(2):257-65. PubMed ID: 10037173
[TBL] [Abstract][Full Text] [Related]
13. The role of hypoxia and p53 in the regulation of angiogenesis in bladder cancer.
Reiher FK; Ivanovich M; Huang H; Smith ND; Bouck NP; Campbell SC
J Urol; 2001 Jun; 165(6 Pt 1):2075-81. PubMed ID: 11371931
[TBL] [Abstract][Full Text] [Related]
14. Effects of the cyclooxygenase inhibitor, piroxicam, in combination with chemotherapy on tumor response, apoptosis, and angiogenesis in a canine model of human invasive urinary bladder cancer.
Mohammed SI; Craig BA; Mutsaers AJ; Glickman NW; Snyder PW; deGortari AE; Schlittler DL; Coffman KT; Bonney PL; Knapp DW
Mol Cancer Ther; 2003 Feb; 2(2):183-8. PubMed ID: 12589035
[TBL] [Abstract][Full Text] [Related]
15. Treatment of human metastatic transitional cell carcinoma of the bladder in a murine model with the anti-vascular endothelial growth factor receptor monoclonal antibody DC101 and paclitaxel.
Inoue K; Slaton JW; Davis DW; Hicklin DJ; McConkey DJ; Karashima T; Radinsky R; Dinney CP
Clin Cancer Res; 2000 Jul; 6(7):2635-43. PubMed ID: 10914704
[TBL] [Abstract][Full Text] [Related]
16. EGFR inhibition fails to suppress vascular proliferation and tumor growth in a Ewing's sarcoma model.
Chernoguz A; Crawford K; Donovan E; Vandersall A; Berglund C; Cripe TP; Frischer JS
J Surg Res; 2012 Mar; 173(1):1-9. PubMed ID: 21658718
[TBL] [Abstract][Full Text] [Related]
17. Harmine suppresses bladder tumor growth by suppressing vascular endothelial growth factor receptor 2-mediated angiogenesis.
Hai-Rong C; Xiang H; Xiao-Rong Z
Biosci Rep; 2019 May; 39(5):. PubMed ID: 30910851
[TBL] [Abstract][Full Text] [Related]
18. Modulation of tumor growth and tumor induced angiogenesis after epidermal growth factor receptor inhibition by ZD1839 in renal cell carcinoma.
Asakuma J; Sumitomo M; Asano T; Asano T; Hayakawa M
J Urol; 2004 Feb; 171(2 Pt 1):897-902. PubMed ID: 14713849
[TBL] [Abstract][Full Text] [Related]
19. Molecular correlates of gefitinib responsiveness in human bladder cancer cells.
Shrader M; Pino MS; Brown G; Black P; Adam L; Bar-Eli M; Dinney CP; McConkey DJ
Mol Cancer Ther; 2007 Jan; 6(1):277-85. PubMed ID: 17237287
[TBL] [Abstract][Full Text] [Related]
20. Transforming growth factor alpha expression drives constitutive epidermal growth factor receptor pathway activation and sensitivity to gefitinib (Iressa) in human pancreatic cancer cell lines.
Pino MS; Shrader M; Baker CH; Cognetti F; Xiong HQ; Abbruzzese JL; McConkey DJ
Cancer Res; 2006 Apr; 66(7):3802-12. PubMed ID: 16585207
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]